Sökning: onr:"swepub:oai:DiVA.org:kth-302036" >
Antibody responses ...
Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2
-
- Havervall, Sebastian (författare)
- Karolinska Institutet,Danderyd Hosp, Karolinska Inst, Dept Clin Sci, S-18288 Stockholm, Sweden.
-
- Marking, Ulrika (författare)
- Karolinska Institutet,Danderyd Hosp, Karolinska Inst, Dept Clin Sci, S-18288 Stockholm, Sweden.
-
- Greilert-Norin, Nina (författare)
- Danderyd Hosp, Karolinska Inst, Dept Clin Sci, S-18288 Stockholm, Sweden.
-
visa fler...
-
- Ng, Henry (författare)
- Uppsala universitet,Science for Life Laboratory, SciLifeLab,Institutionen för medicinsk cellbiologi,Danderyd Hosp, Karolinska Inst, Dept Clin Sci, S-18288 Stockholm, Sweden.
-
- Gordon, Max (författare)
- Karolinska Institutet,Danderyd Hosp, Karolinska Inst, Dept Clin Sci, S-18288 Stockholm, Sweden.
-
- Salomonsson, Ann-Christin (författare)
- Danderyd Hosp, Karolinska Inst, Dept Clin Sci, S-18288 Stockholm, Sweden.
-
- Hellström, Cecilia (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,KTH Royal Inst Technol, Dept Prot Sci, SciLifeLab, Stockholm, Sweden.
-
- Pin, Elisa (författare)
- KTH,Affinitets-proteomik,Science for Life Laboratory, SciLifeLab,KTH Royal Inst Technol, Dept Prot Sci, SciLifeLab, Stockholm, Sweden.
-
- Blom, Kim (författare)
- Karolinska Institutet,Publ Hlth Agcy Sweden, Solna, Sweden.
-
- Mangsbo, Sara, 1981- (författare)
- Uppsala universitet,Science for Life Laboratory, SciLifeLab,Institutionen för farmaceutisk biovetenskap
-
- Phillipson, Mia (författare)
- Uppsala Univ, Dept Med Cell Biol, Sci Life Lab, Uppsala, Sweden.
-
- Klingström, Jonas (författare)
- Karolinska Institutet,Publ Hlth Agcy Sweden, Solna, Sweden.;Karolinska Inst, Ctr Infect Med, Dept Med Huddinge, Stockholm, Sweden.
-
- Hober, Sophia, Professor, 1965- (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Proteinteknologi,KTH Royal Inst Technol, Dept Prot Sci, SciLifeLab, Stockholm, Sweden.
-
- Nilsson, Peter (författare)
- KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,KTH Royal Inst Technol, Dept Prot Sci, SciLifeLab, Stockholm, Sweden.
-
- Åberg, Mikael (författare)
- Uppsala universitet,Science for Life Laboratory, SciLifeLab,Klinisk kemi
-
- Thalin, Charlotte (författare)
- Karolinska Institutet,Danderyd Hosp, Karolinska Inst, Dept Clin Sci, S-18288 Stockholm, Sweden.
-
visa färre...
-
Karolinska Institutet Danderyd Hosp, Karolinska Inst, Dept Clin Sci, S-18288 Stockholm, Sweden (creator_code:org_t)
- Elsevier BV, 2021
- 2021
- Engelska.
-
Ingår i: EBioMedicine. - : Elsevier BV. - 2352-3964. ; 70
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
http://www.thelancet...
-
https://uu.diva-port... (primary) (Raw object)
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
http://kipublication...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Recent reports demonstrate robust serological responses to a single dose of messenger RNA (mRNA) vaccines in individuals previously infected with SARS-CoV-2. Data on immune responses following a single-dose adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein (ChAdOx1 nCoV-19) in individuals with previous SARS-CoV-2 infection are however limited, and current guidelines recommend a two-dose regimen regardless of preexisting immunity. Methods: We compared RBD-specific IgG and RBD-ACE2 blocking antibodies against SARS-CoV-2 wild type and variants of concern following two doses of the mRNA vaccine BNT162b2 in SARS-CoV-2 naive healthcare workers (n=65) and a single dose of the adenovector vaccine ChAdOx1 nCoV-19 in 82 healthcare workers more than (n=45) and less than (n=37) 11 months post mild SARS-CoV-2 infection at time of vaccination. Findings: The post-vaccine levels of RBD-specific IgG and neutralizing antibodies against the SARS-CoV-2 wild type and variants of concern including Delta lineage 1.617.2 were similar or higher in participants receiving a single dose of ChAdOx1 nCoV-19 vaccine post SARS-CoV-2 infection (both more than and less than 11 months post infection) compared to SARS-CoV-2 naive participants who received two doses of BNT162b2 vaccine. Interpretation: Our data support that a single dose ChAdOx1 nCoV-19 vaccine that is administered up to at least 11 months post SARS-CoV-2 infection serves as an effective immune booster. This provides a possible rationale for a single-dose vaccine regimen. (C) 2021 The Author(s). Published by Elsevier B.V.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Infektionsmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Infectious Medicine (hsv//eng)
Nyckelord
- SARS-CoV-2
- Neutralizing antibody response
- Prior infection
- ChAdOx1 nCoV-19
- BNT162b2 vaccine
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Havervall, Sebas ...
-
Marking, Ulrika
-
Greilert-Norin, ...
-
Ng, Henry
-
Gordon, Max
-
Salomonsson, Ann ...
-
visa fler...
-
Hellström, Cecil ...
-
Pin, Elisa
-
Blom, Kim
-
Mangsbo, Sara, 1 ...
-
Phillipson, Mia
-
Klingström, Jona ...
-
Hober, Sophia, P ...
-
Nilsson, Peter
-
Åberg, Mikael
-
Thalin, Charlott ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Infektionsmedici ...
- Artiklar i publikationen
-
EBioMedicine
- Av lärosätet
-
Kungliga Tekniska Högskolan
-
Karolinska Institutet
-
Uppsala universitet